Skip to main content

Table 1 Predictors of response from a stepwise logistic-regression model on combined ‘improver’ criteria and combined ‘non-decliner’ criteria

From: Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Effect

Maximum likelihood estimates

Parameter

Week 24

Week 48

Estimate a

Pr > ChiSq

Estimate a

Pr > ChiSq

‘Improvers’

Treatmentb

Treatment 9.5 mg/24 h patch

−0.580

0.0001

−0.461

0.021

Gender

Female

0.234

0.137

−0.040

0.014

ADAS-cogc

ADAS-cogc

0.044

0.017

−0.438

0.059

ADCS-IADLc

ADCS-IADLc

−0.026

0.050

na

na

MMSEc

MMSE ≤12c

−0.854

<0.0001

na

na

‘Non-decliners’

Treatmentb

Treatment 9.5 mg/24 h patch

−0.337

0.002

−0.270

0.058

Gender

Female

0.218

0.094

na

na

ADAS-cogc

ADAS-cogc

0.031

0.014

na

na

ADCS-IADLc

ADCS-IADLc

na

na

−0.027

0.020

MMSEc

MMSE ≤12c

−0.497

0.002

−0.351

0.040

Weight, versus >80 kg

Weight 50 to 80 kg

−0.363

0.068d

−0.405

0.119d

 

Weight <50 kg

0.208

0.344

  1. aPositive estimate indicates increased odds of response when increasing the value of the covariate, or when in the given category. Negative estimated effect means reduced odds of response. bTreatment effect compares 9.5 mg/24 h to 13.3 mg/24 h rivastigmine patch. cAt DB-BL. dAll categories combined. Candidate covariates were: treatment, gender, ADAS-cog score at DB-BL, ADCS-IADL score at DB-BL, MMSE score of ≤12 at DB-BL and weight category (<50, 50 to 80 and >80 kg). ‘Improver’ = patient with an improvement from DB-BL in ADAS-cog score ≥4 points and a change from DB-BL in ADCS-IADL score ≥0 points; ‘non-decliner’ = patient with a change from DB-BL in ADAS-cog score ≤0 points and a change from DB-BL in ADCS-IADL score ≥0 points. ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; ADCS-IADL, Instrumental domain of the Alzheimer’s Disease Cooperation Study–Activities of Daily Living scale; DB-BL, double-blind baseline; MMSE, Mini-Mental State Examination; na, not applicable because effect not selected as relevant by the stepwise regression model – only variables (effects) with a P-value <0.15 were included in the final model. Treatment was always retained within the model; Pr > ChiSq, P-value of the Chi-Square test.